Sanofi invests €170m to expand flu jab facility

The new facility will allow Sanofi Pasteur, the vaccines business unit of Sanofi, to expand supply of VaxigripTetra. The quadrivalent influenza vaccine contains two A strains (A/H1N1 and A/H3N2) and two B strains (B/Victoria and B/Yamagata) of influenza virus, as recommended by the World Health Organization. The jab is indicated for adults and children from 3 years and older

Sanofi plans to complete the expansion by 2021, and will begin producing vaccines in the new facility in 2022.  The investment adds to other major capital expenditures Sanofi has made in recent years to improve and expand its vaccine production capacities across France, the United States and Mexico.